Literature DB >> 15386332

2-Fluoro-2-deoxy-D-glucose positron emission tomography imaging is predictive of pathologic response and survival after preoperative chemoradiation in patients with esophageal carcinoma.

Stephen G Swisher1, Jeremy Erasmus, Mary Maish, Arlene M Correa, Homer Macapinlac, Jaffer A Ajani, James D Cox, Ritsuko R Komaki, David Hong, Hoon K Lee, Joe B Putnam, David C Rice, W Roy Smythe, Linh Thai, Ara A Vaporciyan, Garrett L Walsh, Tsung-Teh Wu, Jack A Roth.   

Abstract

BACKGROUND: The current study was performed to assess the value of 2-fluoro-2-deoxy-d-glucose positron emission tomography (FDG-PET) in predicting the pathologic response and survival of patients with esophageal carcinoma treated with preoperative chemoradiation (CRT) and tumor resection. Preliminary reports suggest that FDG-PET may be predictive of the response of esophageal carcinoma patients to preoperative CRT.
METHODS: Eighty-three patients with resectable esophageal carcinoma who underwent preoperative CRT and FDG-PET and tumor resection were evaluated for pathologic response to CRT, percent residual tumor, and survival.
RESULTS: The majority of patients in the current study were men (74 of 83 patients; 89%). Most tumors were adenocarcinomas (73 of 83 tumors; 88%) and clinical (EUS)T3/4 (69 tumors; 83%) or N1 (46 tumors; 55%). FDG-PET after preoperative CRT identified pathologic responders but failed to rule out microscopic residual tumor in 13 of 73 cases (18%). Pathologic response was found to correlate with the post-CRT FDG-PET standardized uptake value (SUV) (P = 0.03) and a post-CRT FDG-PET SUV of or 4 was found to be the only preoperative factor to correlate with decreased survival (2-year survival rate of 33% vs. 60%; P = 0.01). On univariate Cox regression analysis, only post-CRT FDG-PET was found to be correlated with post-CRT survival (P = 0.04).
CONCLUSIONS: Post-CRT FDG-PET was found to be predictive of pathologic response and survival in patients with esophageal carcinoma who undergo preoperative CRT. Esophagectomy should still be considered even if the post-CRT FDG-PET scan is normal because microscopic residual disease cannot be ruled out.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15386332     DOI: 10.1002/cncr.20585

Source DB:  PubMed          Journal:  Cancer        ISSN: 0008-543X            Impact factor:   6.860


  71 in total

1.  Inclusion of PET-CT into planning of primary or neoadjuvant chemoradiotherapy of esophageal cancer improves prognosis.

Authors:  Jan-Christopher Metzger; Daniel Wollschläger; Matthias Miederer; Peter Vaupel; Markus Moehler; Heinz Schmidberger; Arnulf Mayer
Journal:  Strahlenther Onkol       Date:  2017-08-02       Impact factor: 3.621

2.  Symptomatic cardiac toxicity is predicted by dosimetric and patient factors rather than changes in 18F-FDG PET determination of myocardial activity after chemoradiotherapy for esophageal cancer.

Authors:  Andre Konski; Tianyu Li; Michael Christensen; Jonathan D Cheng; Jian Q Yu; Kevin Crawford; Oleh Haluszka; Jeffrey Tokar; Walter Scott; Neal J Meropol; Steven J Cohen; Alan Maurer; Gary M Freedman
Journal:  Radiother Oncol       Date:  2012-06-07       Impact factor: 6.280

3.  Early response evaluation and prediction in neoadjuvant-treated patients with esophageal cancer.

Authors:  Joerg Theisen; Bernd Krause; Christian Peschel; Roland Schmid; Hans Geinitz; Helmut Friess
Journal:  World J Gastrointest Surg       Date:  2009-11-30

4.  Positron emission tomography's changing significance in the treatment of esophageal cancer.

Authors:  Shane Hopkins; Gary Yang
Journal:  World J Gastrointest Oncol       Date:  2009-10-15

5.  The role of qualitative and quantitative analysis of F18-FDG positron emission tomography in predicting pathologic response following chemoradiotherapy in patients with esophageal carcinoma.

Authors:  Tracy Klayton; Tianyu Li; Jian Q Yu; Lanea Keller; Jonathan Cheng; Steven J Cohen; Neal J Meropol; Walter Scott; Meng Xu-Welliver; Andre Konski
Journal:  J Gastrointest Cancer       Date:  2012-12

Review 6.  The added value of metabolic imaging with FDG-PET in oesophageal cancer: prognostic role and prediction of response to treatment.

Authors:  Emilio Bombardieri
Journal:  Eur J Nucl Med Mol Imaging       Date:  2006-07       Impact factor: 9.236

Review 7.  [18F-FDG-PET in therapy response of esophageal cancer].

Authors:  H A Wieder; K Herrmann; K Ott; B J Krause
Journal:  Radiologe       Date:  2007-02       Impact factor: 0.635

8.  Outcomes of patients with esophageal cancer staged with [¹⁸F]fluorodeoxyglucose positron emission tomography (FDG-PET): can postchemoradiotherapy FDG-PET predict the utility of resection?

Authors:  Arta Monir Monjazeb; Greg Riedlinger; Mebea Aklilu; Kim R Geisinger; Girish Mishra; Scott Isom; Paige Clark; Edward A Levine; A William Blackstock
Journal:  J Clin Oncol       Date:  2010-09-27       Impact factor: 44.544

9.  Comparison of uptake characteristics and prognostic value of 201Tl and 18F-FDG in esophageal cancer.

Authors:  Hyun Woo Chung; Kyung-Han Lee; Eun Jeong Lee; Su Jin Lee; Young Seok Cho; Joon Young Choi; Young Mog Shim; Kwhanmien Kim; Byung-Tae Kim
Journal:  World J Surg       Date:  2008-01       Impact factor: 3.352

10.  Diagnostic accuracy of ¹⁸F-FDG PET/CT for detection of suspected recurrence in patients with oesophageal carcinoma.

Authors:  Punit Sharma; Sachin Jain; Sellam Karunanithi; Sujoy Pal; Pramod Kumar Julka; Sanjay Thulkar; Arun Malhotra; Chandrasekhar Bal; Rakesh Kumar
Journal:  Eur J Nucl Med Mol Imaging       Date:  2014-01-17       Impact factor: 9.236

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.